An ideal anti-obesity medication should achieve substantial and sustained weight reduction while maintaining an acceptable safety profile and minimizing adverse effects. However, the regulation of energy balance is governed by highly complex and redundant physiological networks that interact extensively with multiple biological systems. Consequently, the history of anti-obesity drug development has been marked by numerous setbacks, including failures during clinical development and the withdrawal of approved agents due to unforeseen safety concerns. Several therapeutic approaches targeting metabolic tissues such as adipose tissue, liver, and skeletal muscle have demonstrated promising results in preclinical studies. The particular attention has been directed toward gastrointestinal peptide hormones involved in hunger and satiety signaling, including ghrelin, cholecystokinin (CCK), peptide YY (PYY), and glucagon-like peptide-1 (GLP-1). Similarly, improved knowledge of leptin-mediated pathways and hypothalamic mechanisms regulating energy balance has expanded opportunities for the development of innovative anti-obesity therapies. Among these emerging therapeutic options, GLP-1 receptor agonists have demonstrated remarkable clinical success. Originally developed for the treatment of type 2 diabetes mellitus, these agents have consistently shown clinically meaningful reductions in body weight, thereby establishing a new benchmark for obesity pharmacotherapy. Their success has stimulated the development of additional incretin-based therapies and has reinforced the concept that targeting multiple pathways involved in appetite regulation and energy expenditure may offer superior therapeutic outcomes. Given the multifactorial nature of obesity, there is growing recognition that future treatment strategies may require a paradigm shift beyond single-target interventions. Similar to the management of chronic diseases such as diabetes and hypertension, combination therapies employing lower doses of multiple agents that act through complementary mechanisms may provide enhanced efficacy while minimizing adverse effects.